×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| WOCKHARDT LTD. | 4380.0 | 690.0 | 4130.0 | 4.25 | 23,756 | 466.0 |
| PFIZER LTD. | 6702.2 | 1917.5 | 6030.5 | 41.91 | 23444 | 153.0 |
| Eris Lifesciences Limited | 6013.2 | 999.9 | 5786.4 | 7.33 | 23312 | 60.2 |
Wockhardt Ltd, with Security Code 532300, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 291.0 | 251.0 | 260.0 | 288.0 | 355.0 | 352.0 | 370.0 | 325.0 | 355.0 | 413.0 |
| Expenses | 321.0 | 256.0 | 270.0 | 263.0 | 401.0 | 272.0 | 321.0 | 263.0 | 249.0 | 282.0 |
| Operating Profit | -30.0 | -5.0 | -10.0 | 25.0 | -46.0 | 80.0 | 49.0 | 62.0 | 106.0 | 131.0 |
| OPM % | -10.31% | -1.99% | -3.85% | 8.68% | -12.96% | 22.73% | 13.24% | 19.08% | 29.86% | 31.72% |
| Other Income | -156.0 | -8.0 | 6.0 | 5.0 | 24.0 | 27.0 | 11.0 | 6.0 | 14.0 | 25.0 |
| Interest | 58.0 | 58.0 | 59.0 | 61.0 | 59.0 | 58.0 | 53.0 | 48.0 | 40.0 | 41.0 |
| Depreciation | 45.0 | 44.0 | 44.0 | 43.0 | 45.0 | 43.0 | 43.0 | 42.0 | 40.0 | 46.0 |
| Profit before tax | -104.0 | -101.0 | -107.0 | -74.0 | -126.0 | 6.0 | -36.0 | -22.0 | 40.0 | 69.0 |
| Tax % | 3.5% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -299.0 | -115.0 | -107.0 | -74.0 | -126.0 | 6.0 | -36.0 | -22.0 | 40.0 | 69.0 |
| EPS in Rs | -20.8 | -8.01 | -7.39 | -5.14 | -8.71 | 0.39 | -2.34 | -1.4 | 0 | 4.25 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 699.0 | 678.0 | 644.0 | 753.0 | 701.0 | 700.0 | 739.0 | 809.0 | 721.0 | 743.0 |
| Expenses | 654.0 | 675.0 | 628.0 | 681.0 | 664.0 | 803.0 | 648.0 | 699.0 | 593.0 | 679.0 |
| Operating Profit | 45.0 | 3.0 | 16.0 | 72.0 | 37.0 | -103.0 | 91.0 | 110.0 | 128.0 | 64.0 |
| OPM % | 6.44% | 0.44% | 2.48% | 9.56% | 5.28% | -14.71% | 12.31% | 13.6% | 17.75% | 8.61% |
| Other Income | -1.0 | -64.0 | 0.0 | 24.0 | 8.0 | 54.0 | 30.0 | 9.0 | 8.0 | 15.0 |
| Interest | 83.0 | 76.0 | 79.0 | 76.0 | 77.0 | 73.0 | 73.0 | 73.0 | 60.0 | 48.0 |
| Depreciation | 66.0 | 56.0 | 55.0 | 55.0 | 55.0 | 58.0 | 54.0 | 55.0 | 55.0 | 53.0 |
| Profit before tax | -102.0 | -97.0 | -104.0 | -35.0 | -87.0 | -180.0 | -6.0 | -9.0 | 21.0 | -22.0 |
| Tax % | -2.9% | 22.8% | 15.3% | 108.6% | -1.1% | -1.7% | -166.7% | -77.8% | 4.8% | 0% |
| Net Profit | -102.0 | -237.0 | -136.0 | -73.0 | -86.0 | -177.0 | -16.0 | -16.0 | 20.0 | -45.0 |
| EPS in Rs | -6.62 | -14.37 | -9.28 | -5.37 | -5.75 | -11.64 | -0.95 | -1.47 | 0.91 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -4% |
| 5 Years: | -6% |
| 3 Years: | 5% |
| TTM: | 29% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| TTM: | 56% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 45% |
| 3 Years: | 68% |
| 1 Year: | 138% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -5% |
| 5 Years: | -5% |
| 3 Years: | 1% |
| TTM: | 7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| TTM: | 66% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 45% |
| 3 Years: | 68% |
| 1 Year: | 138% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|